Clarivate’s Market Access offerings combine trusted data, expert consulting, and pharmacist-validated insights to help life sciences teams overcome today’s toughest access and pricing challenges. We connect Fingertip’s validated formulary, restrictions, enrolled lives, and real-world evidence with consulting expertise to deliver a defensible, future-ready framework. From strategy through execution, we empower clients to make smarter, faster decisions that help bring treatments to patients sooner.
DRG Fingertip is the gold standard for market access delivering trusted, pharmacist validated AI-powered data and expert authored insights.
• Obtain the most accurate coverage, policy, and restrictions data, curated by pharmacists, powered by AI on a single platform to guide your market access strategy and decisions.
• Gain access to essential context behind the coverage with expert-authored insights at every level—national, regional, local—to anticipate payer trends, segment key stakeholders, and navigate market dynamics.
• Accelerate pull-through by helping clients identify and overcome hidden barriers (tiering, step edits, prior authorizations) that slow uptake.
• Unlock insights into CRM-ready outputs to streamline workflows, reduce manual validation, and increase agility.
Market Access Consulting provides expertise as an extension of your team.
• Leverage our deep strategic expertise built on decades of hands-on experience in launch readiness, pricing, reimbursement, HUB services, and biopharma market access.
• Navigate high-cost, high-complexity markets through proven therapy-area leadership spanning oncology, cell therapies, immunology, neuroscience, and specialty pharma.
• Accelerate uptake, reduce risk, and strengthen investment decisions by translating policy and payer shifts (IRA, OBBB, MFN, 340B) into actionable, market-ready strategies.
DRG Fusion turns real-world data into configurable, Ai-powered insights that help teams uncover the why behind adoption and uptake - and turn insight into clear action. DRG Fusion delivers:
• A unified view of claims, access, and patient journey data
• Configurable workflows aligned to your business rules
• Action-oriented AI-powered analytics for rapid, self-serve insights—helping teams decide what to do next
With DRG Fusion, commercial teams can size opportunities, refine targeting and deploy resources strategically —all within one flexible platform.
Thought Leadership:
Clarivate is leading critical conversations on how IRA, OBBB, and MFN pricing will reshape specialty pharma and payer dynamics—helping the industry navigate unprecedented complexity.
In January, Clarivate launched its flagship Drugs to Watch 2026 report, spotlighting 11 therapies poised to redefine treatment paradigms across metabolic disease and obesity, rare and chronic disease breakthroughs, oncology, immunology and women’s health. The report reveals the commercial and regulatory challenges shaping tomorrow’s launches.
Our integrated data, transparent AI-enabled solutions and expertise help life science leaders accelerate development, de-risk decisions and build evidence-based launch strategies in this ever-changing landscape.